Recent CTMX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:01:57 PM
- CytomX Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/16/2024 08:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/13/2024 08:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:41:03 PM
- CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:04:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:21 PM
- CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) • GlobeNewswire Inc. • 05/07/2024 08:15:00 PM
- CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/11/2024 08:30:38 PM
- CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/11/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:02:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:00:31 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
- CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024 • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- CytomX Therapeutics to Present at Upcoming March Investor Conferences • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 01:44:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 01:41:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/20/2024 01:40:22 AM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM